Explanipedia

Dopa Responsiveness in Parkinson's Disease Open

Sacha E. Gandhi, Anahita Nodehi, Michael Lawton, Katherine A. Grosset, Vicky Marshall , et al. · 2024

Background Dopaminergic responsiveness is a defining feature of Parkinson's disease (PD). However, there is limited information on how this evolves over time. Objectives To examine serial dopaminergic responses, if there are distinct patte…

Genome-wide determinants of mortality and motor progression in Parkinson’s disease Open

Manuela Tan, Michael Lawton, Miriam I. Pollard, Emmeline Brown, Raquel Real , et al. · 2024

There are 90 independent genome-wide significant genetic risk variants for Parkinson’s disease (PD) but currently only five nominated loci for PD progression. The biology of PD progression is likely to be of central importance in defining …

Dopa responsiveness in Parkinson’s disease Open

Sacha E. Gandhi, Anahita Nodehi, Michael Lawton, Katherine A. Grosset, Vicky Marshall , et al. · 2024

Background Dopaminergic responsiveness is a defining feature of Parkinson’s disease (PD). However, there is limited information on how this evolves over time. Objectives To examine serial dopaminergic responses, if there are distinct patte…

Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging Open

Nicholas Heng, Naveed Malek, Michael Lawton, Anahita Nodehi, Vanessa Pitz , et al. · 2023

Background Neuropathological studies, based on small samples, suggest that symptoms of Parkinson's disease (PD) emerge when dopamine/nigrostriatal loss is around 50–80%. Functional neuroimaging can be applied in larger numbers during life,…

Genome-wide determinants of mortality and motor progression in Parkinson’s disease Open

Manuela Tan, Michael Lawton, Miriam I. Pollard, Emmeline Brown, Raquel Real , et al. · 2022

Background There are 90 genetic risk variants for Parkinson’s disease (PD) but currently only five nominated loci for PD progression. The biology of PD progression is likely to be of central importance in defining mechanisms that can be us…

Serum neurofilament light as a biomarker for prognosis in patients with newly diagnosed Parkinson’s disease Open

Nirosen Vijiaratnam, Michael Lawton, Amanda Heslegrave, Tong Guo, Manuela Tan , et al. · 2021

Background Patients with Parkinson’s disease (PD) have variable disease progression. More accurate prediction of progression could improve clinical trial design. Although some variance in clinical progression can be predicted by age at ons…

Author response for "Comparison between four published definitions of hyposmia in Parkinson's disease" Open

Sofia Kanavou, Vanessa Pitz, Michael Lawton, Naveed Malek, Katherine A. Grosset , et al. · 2021

Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease Open

Manuela Tan, Michael Lawton, Edwin Jabbari, Regina H. Reynolds, Hirotaka Iwaki , et al. · 2020

Background There are currently no treatments that stop or slow the progression of Parkinson's disease (PD). Case–control genome‐wide association studies have identified variants associated with disease risk, but not progression. The object…

Genome-wide association studies of cognitive and motor progression in Parkinson's disease Open

Manuela Tan, Michael Lawton, Edwin Jabbari, Regina H. Reynolds, Hirotaka Iwaki , et al. · 2020

Background: There are currently no treatments that stop or slow the progression of Parkinson's disease (PD). Case-control genome-wide association studies (GWASs) have identified variants associated with disease risk, but not progression. O…

The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review Open

Vanessa Pitz, Naveed Malek, Edward S. Tobias, Katherine A. Grosset, Steve Gentleman , et al. · 2019

Background A good response to levodopa is a key feature of Parkinson's disease (PD), and a poor response suggests an alternative diagnosis, but the extent of variation in the levodopa response in definite PD is not well defined. Literature…

Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study Open

Manuela Tan, Naveed Malek, Michael Lawton, Leon Hubbard, Alan Pittman , et al. · 2019

Our objective was to define the prevalence and clinical features of genetic Parkinson’s disease in a large UK population-based cohort, the largest multicentre prospective clinico-genetic incident study in the world. We collected demographi…

L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression Open

Naveed Malek, Sofia Kanavou, Michael Lawton, Vanessa Pitz, Katherine A. Grosset , et al. · 2019

Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression Open

Michael Lawton, Yoav Ben‐Shlomo, Margaret May, Fahd Baig, Thomas R. Barber , et al. · 2018

Objectives To use a data-driven approach to determine the existence and natural history of subtypes of Parkinson’s disease (PD) using two large independent cohorts of patients newly diagnosed with this condition. Methods 1601 and 944 patie…

Features of <i>GBA</i>-associated Parkinson’s disease at presentation in the UK <i>Tracking Parkinson’s</i> study Open

Naveed Malek, Rimona S. Weil, Catherine Bresner, Michael Lawton, Katherine A. Grosset , et al. · 2018

Objectives To examine the influence of the glucocerebrosidase ( GBA ) mutation carrier state on age at onset of Parkinson’s disease (PD), the motor phenotype and cognitive function at baseline assessment in a large cohort of UK patients. W…

Patient-centred improvement to repeat prescribing using the Always Event concept Open

Katherine A. Grosset, Elaine Deary, Nancy El‐Farargy · 2017

Repeat prescriptions are prescriptions issued to a patient for a second or subsequent time without requiring a consultation with a doctor. Repeat prescribing is common and an efficient system is necessary to deliver a high-quality service.…

Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases Open

Naveed Malek, Michael Lawton, Katherine A. Grosset, Nin Bajaj, Roger A. Barker , et al. · 2017

Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study Open

Naveed Malek, Michael Lawton, Katherine A. Grosset, Nin Bajaj, Roger A. Barker , et al. · 2016

Background Autonomic dysfunction is common in the later stages of Parkinson's disease ( PD ), but less is known about its presence and severity in early disease. Objective To analyze features of autonomic dysfunction in recent onset PD cas…

Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts Open

Diane M.A. Swallow, Michael Lawton, Katherine A. Grosset, Naveed Malek, Johannes Klein , et al. · 2016

GN11NE062, NCT02881099.

Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease Open

Michael Lawton, Joshua Shulman, Fahd Baig, Claudio Ruffmann, Eilidh Barron , et al. · 2016

Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease Open

Naveed Malek, Michael Lawton, Diane M.A. Swallow, Katherine A. Grosset, Sarah Marrinan , et al. · 2016

Objective The purpose of this study was to examine the relationship between vascular disease (and vascular risk factors), cognition and motor phenotype in Parkinson's disease (PD). Methods Recently diagnosed PD cases were enrolled in a mul…

Tracking Parkinson’s: Study Design and Baseline Patient Data Open

Naveed Malek, Diane M.A. Swallow, Katherine A. Grosset, Michael Lawton, Sarah Marrinan , et al. · 2015

We have established a large clinical PD cohort, consisting of young onset and recent onset cases, which is designed to evaluate variation in clinical expression, in relation to genetic influences, and which offers a platform for future ima…

Variation in recent onset Parkinson’s disease: implications for pre-motor detection Open

D.M.A. Swallow, Michael Lawton, Katherine A. Grosset, Naveed Malek, Callum Smith , et al. · 2015

Olfaction testing in Parkinson’s disease and controls: a comparison of two techniques Open

E. Barrón, D.M.A. Swallow, Naveed Malek, Michael Lawton, Katherine A. Grosset , et al. · 2015

Katherine A. Grosset YOU? Author Swipe